RT Journal Article SR Electronic T1 Outbreaks of Covid-19 Variants in Prisons: A Mathematical Modeling Analysis of Vaccination and Re-Opening Policies JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.05.03.21256525 DO 10.1101/2021.05.03.21256525 A1 Theresa Ryckman A1 Elizabeth T. Chin A1 Lea Prince A1 David Leidner A1 Elizabeth Long A1 David M. Studdert A1 Joshua A. Salomon A1 Fernando Alarid-Escudero A1 Jason R. Andrews A1 Jeremy D. Goldhaber-Fiebert YR 2021 UL http://medrxiv.org/content/early/2021/05/05/2021.05.03.21256525.abstract AB Background Residents of correctional facilities have experienced disproportionately higher rates of SARS-CoV-2 infection and Covid-19-related mortality. To protect against outbreaks, many prisons and jails imposed heavy restrictions on in-person activities, which are now beginning to lift. Uncertainty surrounds the safety of these moves.Methods and Findings We obtained system-wide resident-day level data for the California state prison system, the nation’s third largest. We used the data to develop a transmission-dynamic stochastic microsimulation model that projects the impact of various policy scenarios on risks of SARS-CoV-2 infections and related hospitalization among residents after an initial infection is introduced to a prison. The policy scenarios vary according to levels of vaccine coverage, baseline immunity, resumption of activities, and use of non-pharmaceutical interventions (e.g., masking, physical distancing). The analyses were conducted across 5 types of prisons that differed in their residential layouts, security levels, and resident demographics.If a viral variant is introduced into a prison that has resumed pre-2020 contact levels, has moderate vaccine coverage, and has no baseline immunity, 23-74% of residents are expected to be infected over 200 days. High vaccination coverage coupled with use of non-pharmaceutical measures reduces cumulative infections to 2-54% of residents. In prisons consisting mostly of dormitory housing, even with high vaccine coverage and non-pharmaceutical interventions, resumption of in-person activities is associated with substantial risk, unless there is high baseline immunity (e.g., ≥50%) from prior outbreaks. In prisons consisting mostly of cell housing, <10% of residents are expected to become infected, even with no baseline immunity. However, hospitalization risks are substantial in prisons that house medically vulnerable populations, even for prisons consisting mostly of cells. Risks of large outbreaks are substantially higher if there is continued introduction of infections into a prison. Some findings may not be transportable to other carceral settings, and our assumptions regarding viral variants will not be accurate for all variants.Conclusions Balancing the benefits of resuming normal in-person activities against the risks of Covid-19 outbreaks is a difficult challenge for correctional systems. The policy choices are not strictly binary. To protect against viral variants, prisons should focus on achieving both high vaccine coverage and maintaining widespread use of non-pharmaceutical interventions. With both in place, some prisons, especially those with lower room occupancy that have already had large outbreaks, could safely resume in-person activities, while continuing testing and measures to protect the medically-vulnerable.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the Stanford COVID-19 Emergency Response Fund, established with a gift from the Horowitz Family Foundation; the National Institute on Drug Abuse (R37-DA15612); the Centers for Disease Control and Prevention (though the Council of State and Territorial Epidemiologists, NU38OT000297-02); the National Science Foundation Graduate Research Fellowship (DGE-1656518); the Stanford Graduate Fellowship in Science and Engineering, and the Open Society Foundations (OR2020-69521). Advanced Micro Devices, Inc. (AMD) provided a donation of servers. The funders had no role in the study design, conduct, reporting, or decision to publish.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Stanford University Institutional Review Board approved the protocol (IRB-55835).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe mathematical model used in the manuscript is parameterized by data from public sources and non-publicly available data obtained via a Data Use Agreement between Stanford University and the California Department of Corrections and Rehabilitation.